keyword
MENU ▼
Read by QxMD icon Read
search

Ribavirin

keyword
https://www.readbyqxmd.com/read/27925386/interferon-free-therapies-for-patients-with-chronic%C3%A2-hepatitis-c-genotype-3-infection-a-systematic-review
#1
Vicente Gimeno-Ballester, María Buti, Ramón San Miguel, Mar Riveiro, Rafael Esteban
INTRODUCTION: Treatment of hepatitis C virus (HCV) infection with genotype 3 remains a challenge. The HCV elimination rate with direct acting antivirals (DAAs) is lower than the values reported for other HCV genotypes. In addition, genotype 3 infected patients have a higher risk of disease progression and hepatocellular carcinoma. The aim of this study was to review the relevant literature concerning treatment of HCV genotype 3 patients with interferon-free regimens. MATERIAL AND METHODS: A literature search was conducted in the PubMed/Medline, Embase, and Web of Science electronic databases...
December 7, 2016: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/27925355/epigenetic-analysis-of-the-ifn%C3%AE-3-gene-identifies-a-novel-marker-for-response-to-therapy-in-hcv-infected-subjects
#2
Jeffrey F Waring, J Wade Davis, Emily Dumas, Daniel Cohen, Kenneth Idler, Stephen Abel, Robert Georgantas, Thomas Podsadecki, Sandeep Dutta
Chronic hepatitis C virus (HCV) infection is characterized by high inter-individual variability in response to pegylated interferon and ribavirin. A genetic polymorphism on chromosome 19 (rs12979860) upstream of interferon-λ-3 (IFNλ3) is associated with a 2-fold change in sustained virologic response rate after 48 weeks of treatment with pegylated interferon/ribavirin in HCV genotype 1 (GT1) treatment-naïve patients. We conducted epigenetic analysis on the IFNλ3 promoter to investigate whether DNA methylation is associated with response to HCV therapy...
December 7, 2016: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/27924186/treatment-of-chronic-hepatitis-c-infection-with-sofosbuvir-based-regimens-in-a-commercially-insured-patient-population
#3
John Barron, Yiqiong Xie, Sze-Jung Wu, Jeff White, Joseph Singer, Bernard Tulsi, Alan Rosenberg
BACKGROUND: The response to treatment with direct-acting antiviral agents in patients with chronic hepatitis C virus (HCV) is not well-characterized in the real-world setting. OBJECTIVE: To describe patients' response to 3 sofosbuvir-based treatment regimens among commercially insured patients with chronic HCV. METHODS: In this observational study, we identified patients with HCV who started sofosbuvir treatment with 1 of 3 sofosbuvir-based regimens between December 1, 2013, and April 30, 2014, in the HealthCore Integrated Research Database, a large managed care repository...
September 2016: American Health & Drug Benefits
https://www.readbyqxmd.com/read/27923693/post-treatment-resistance-analysis-of-hepatitis-c-virus-from-phase-2-and-3-clinical-trials-of-ledipasvir-sofosbuvir
#4
David Wyles, Hadas Dvory-Sobol, Evguenia S Brian Svarovskaia Doehle, Ross Martin, Nezam H Afdhal, Kris V Kowdley, Eric Lawitz, Diana M Brainard, Michael D Miller, Hongmei Mo, Edward J Gane
BACKGROUND & AIMS: Ledipasvir/sofosbuvir combination treatment in phase 3 clinical trials, resulted in sustained viral suppression in 94%-99% of patients. Characterization of drug resistance in treatment failures may help inform retreatment options. METHODS: We performed NS5A and NS5B deep sequencing of HCV from patients infected with genotype (GT) 1 who participated in ledipasvir/sofosbuvir phase 2 and 3 clinical trials. RESULTS: Fifty-one of 2144 (2...
December 3, 2016: Journal of Hepatology
https://www.readbyqxmd.com/read/27920566/hcverso1-and-2-faldaprevir-with-deleobuvir-bi-207127-and-ribavirin-for-treatment-na%C3%A3-ve-patients-with-chronic-hepatitis-c-virus-genotype-1b-infection
#5
Christoph Sarrazin, Francesco Castelli, Pietro Andreone, Maria Buti, Massimo Colombo, Stanislas Pol, Filipe Calinas, Massimo Puoti, Antonio Olveira, Mitchell Shiffman, Jerry O Stern, George Kukolj, Michael Roehrle, Stella Aslanyan, Qiqi Deng, Richard Vinisko, Federico J Mensa, David R Nelson
The interferon-free combination of once-daily faldaprevir 120 mg, twice-daily deleobuvir 600 mg, and weight-based ribavirin was evaluated in two Phase III studies (HCVerso1, HCVerso2) in hepatitis C virus genotype-1b-infected, treatment-naïve patients, including those ineligible for peginterferon (HCVerso2). Patients without cirrhosis were randomized to 16 weeks (Arm 1; n=208 HCVerso1, n=213 HCVerso2) or 24 weeks (Arm 2; n=211 in both studies) of faldaprevir + deleobuvir + ribavirin. Patients with compensated cirrhosis received open-label faldaprevir + deleobuvir + ribavirin for 24 weeks (Arm 3; n=51, n=72)...
2016: Clinical and Experimental Gastroenterology
https://www.readbyqxmd.com/read/27920482/hepatitis-c-virus-therapy-with-peg-interferon-and-ribavirin-in-myanmar-a-resource-constrained-country
#6
Naomi Khaing Than Hlaing, Debolina Banerjee, Robert Mitrani, Soe Htet Arker, Kyaw San Win, Nyan Lin Tun, Zaw Thant, Khin Maung Win, K Rajender Reddy
AIM: To investigate peg-interferon (peg-IFN) and ribavirin (RBV) therapy in Myanmar and to predict sustained virologic response (SVR). METHODS: This single-center, open-label, study was conducted in Myanmar between 2009 and 2014. A total of 288 patients infected with HCV genotypes 1, 2, 3 and 6 were treated with peg-IFN alpha-2a (180 μg/wk) or alpha-2b (50 to 100 μg as a weight-based dose) and RBV as a weight-based dose (15 mg/kg/d). Treatment duration was 48 wk for genotypes 1 and 6, 24 wk for genotype 2, and 24 or 48 wk for genotype 3 based on rapid virologic response (RVR)...
November 21, 2016: World Journal of Gastroenterology: WJG
https://www.readbyqxmd.com/read/27919899/pharmacokinetic-evaluation-of-darunavir-administered-once-or-twice-daily-in-combination-with-ritonavir-or-the-three-direct-acting-antiviral-regimen-of-ombitasvir-paritaprevir-ritonavir-and-dasabuvir-in-adults-co-infected-with-hepatitis-c-and-human-immunodeficiency
#7
Jennifer R King, Amit Khatri, Roger Trinh, Rolando M Viani, Bifeng Ding, Jiuhong Zha, Rajeev Menon
BACKGROUND: The three-direct acting antiviral (3D) regimen containing ombitasvir, paritaprevir, ritonavir and dasabuvir ± ribavirin (RBV) is approved for treatment of HCV GT1/HIV-1 co-infection. Results of a pharmacokinetic substudy of 3D and darunavir are presented. METHODS: HCV/HIV-1 infected subjects were randomized to maintain a darunavir 800 mg once daily (QD) or switch to a darunavir 600 mg twice daily (BID) based antiretroviral regimen. On Study Day 1, subjects received 3D and RBV plus darunavir for 12 weeks...
December 5, 2016: Antimicrobial Agents and Chemotherapy
https://www.readbyqxmd.com/read/27919709/evaluation-of-anti-zika-virus-activities-of-broad-spectrum-antivirals-and-nih-clinical-collection-compounds-using-a-cell-based-high-throughput-screen-assay
#8
Robert S Adcock, Yong-Kyu Chu, Jennifer E Golden, Dong-Hoon Chung
Recent studies have clearly underscored the association between Zika virus (ZIKV) and severe neurological diseases such as microcephaly and Guillain-Barre syndrome. Given the historical complacency surrounding this virus, however, no significant antiviral screenings have been performed to specifically target ZIKV. As a result, there is an urgent need for a validated screening method and strategy that is focused on highlighting potential anti-ZIKV inhibitors that can be further advanced via rigorous validation and optimization...
December 2, 2016: Antiviral Research
https://www.readbyqxmd.com/read/27917261/anti-hepatitis-c-virus-drugs-and-kidney
#9
REVIEW
Paul Carrier, Marie Essig, Marilyne Debette-Gratien, Denis Sautereau, Annick Rousseau, Pierre Marquet, Jérémie Jacques, Véronique Loustaud-Ratti
Hepatitis C virus (HCV) mainly targets the liver but can also induce extrahepatic manifestations. The kidney may be impacted via an immune mediated mechanism or a cytopathic effect. HCV patients are clearly at a greater risk of chronic kidney disease (CKD) than uninfected patients are, and the presence of CKD increases mortality. Interferon-based therapies and ribavirin are difficult to manage and are poorly effective in end-stage renal disease and hemodialysis. These patients should be given priority treatment with new direct anti-viral agents (DAAs) while avoiding peginterferon and ribavirin...
November 18, 2016: World Journal of Hepatology
https://www.readbyqxmd.com/read/27917084/sofosbuvir-and-simeprevir-combination-therapy-for-hcv-genotype-1-infection-results-of-a-single-center-va-experience
#10
Seth N Sclair, Maria Del Pilar Hernandez, Evan Vance, Dani Gilinski, Helen Youtseff, Maribel Toro, Marie Antoine, Lennox J Jeffers, Adam Peyton
Treatment of chronic hepatitis C virus (HCV) infection remains a priority in the veterans affairs (VA) health care system nationwide, as there is a high burden of liver disease due to HCV infection among US veterans. The combination of sofosbuvir and simeprevir was the first all-oral antiviral regimen used in clinical practice to treat veterans with HCV infection. In this study, we report a single-center experience showing both the feasibility and effectiveness of this all-oral combination to treat HCV genotype 1 infection...
August 2016: Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/27914803/effectiveness-of-direct-acting-antivirals-in-hepatitis-c-virus-infection-in-haemodialysis-patients
#11
Soraya Abad, Almudena Vega, Diego Rincón, Eduardo Hernández, Evangelina Mérida, Nicolás Macías, Raquel Muñoz, Mónica Milla, Jose Luño, Juan Manuel López-Gómez
Hepatitis C virus (HCV) infection is highly prevalent among patients on haemodialysis and leads to a poorer prognosis compared to patients who do not have said infection. Treatment with interferon and ribavirin is poorly tolerated and there are limited data on the experience with new direct-acting antivirals (DAAs). The aim of this study is to retrospectively analyse the current prevalence of HCV infection and efficacy and safety results with different DAA regimens in the haemodialysis population of 2hospital areas...
November 30, 2016: Nefrología: Publicación Oficial de la Sociedad Española Nefrologia
https://www.readbyqxmd.com/read/27913223/hepatitis-e-virus-infection-beyond-the-liver
#12
REVIEW
S Pischke, J Hartl, S D Pas, A W Lohse, B C Jacobs, A A van der Eijk
Hepatitis E virus (HEV) infections are not limited to the liver but may also affect other organs. Several diseases, including Guillain-Barré syndrome, neuralgic amyotrophy, glomerulonephritis, cryoglobulinemia, pancreatitis, lymphoma, thrombopenia, meningitis, thyreoiditis and myocarditis have been observed in the context of hepatitis E. To date the definite pathophysiological links between HEV and extrahepatic manifestations are not yet established. However, it is suggested that HEV-infection might be causative based on serological studies, case series, in vitro data and animal models...
November 29, 2016: Journal of Hepatology
https://www.readbyqxmd.com/read/27910116/the-cost-effectiveness-of-testing-for-ns5a-resistance-associated-polymorphisms-at-baseline-in-genotype-1a-infected-treatment-na%C3%A3-ve-and-treatment-experienced-subjects-treated-with-all-oral-elbasvir-grazoprevir-regimens-in-the-united-states
#13
E H Elbasha, M N Robertson, C Nwankwo
BACKGROUND: The presence of baseline NS5A resistance-associated variants (RAVs) impacted treatment response in HCV genotype 1a (GT1a)-infected patients treated with elbasvir/grazoprevir (EBR/GZR) for 12 weeks, but not patients treated with EBR/GZR and ribavirin (RBV) for 16 weeks. AIM: We assessed the cost-effectiveness of baseline testing for NS5A RAVs in EBR/GZR-treated patients compared without testing and with current treatments for GT1a patients. METHODS: We simulated the course of treatment with EBR/GZR, ledipasvir/sofosbuvir (LDV/SOF) and ombitasvir/paritaprevir/ritonavir+dasabuvir (3D) with or without RBV and natural history of disease of GT1a patients...
December 1, 2016: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/27905669/secondary-prophylaxis-of-hepatocellular-carcinoma-the-comparison-of-direct-acting-antivirals-with-pegylated-interferon-and-untreated-cohort
#14
R Vukotic, R Di Donato, F Conti, A Scuteri, C Serra, P Andreone
During the past two decades, several studies showed reduced rates of hepatocellular carcinoma recurrence in patients with HCV-related cirrhosis after interferon-based antiviral therapies respect to untreated controls, even without reaching viral clearance. The recent development of new all-oral regimens with direct-acting antivirals has radically improved the therapeutic management of hepatitis C. Nevertheless, paradoxical, or at least unexpected, high rates of both occurrence and recurrence of hepatocellular carcinoma after a treatment with direct-acting antivirals, have been reported in the recent literature...
December 1, 2016: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/27905173/hepatitis-c-virus-genotype-4-genotype-1-s-little-brother
#15
REVIEW
J Llaneras, M Riveiro-Barciela, M Buti, R Esteban
Treatment for hepatitis C virus genotype 4 infection has undergone a major advance over the past 5 years with the emergence of direct-acting antiviral agents. Previously, genotype 4 treatment had been limited to the combination of pegylated interferon and ribavirin, with low rates of sustained virological response. The combinations of new direct-acting agents have resulted in a radical improvement in hepatitis C therapy. Much of the currently available efficacy and safety information in the treatment of genotype 4 has been extrapolated through the results of genotype 1...
December 1, 2016: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/27904617/the-interferon-lambda-4-rs368234815-predicts-treatment-response-to-pegylated-interferon-alpha-and-ribavirin-in-hemophilic-patients-with-chronic-hepatitis-c
#16
Maryam Keshvari, Seyed Moayed Alavian, Bita Behnava, Ali Pouryasin, Heidar Sharafi
BACKGROUND: A dinucleotide variant rs368234815 in interferon lambda 4 (IFNL4) gene was recently found to be associated with the hepatitis C virus (HCV) treatment response. This study aimed to assess the impact of IFNL4 rs368234815 polymorphism on treatment response to pegylated-IFN alpha (Peg-IFN-α) and ribavirin (RBV) in hemophilic patients with chronic hepatitis C (CHC). MATERIALS AND METHODS: In this retrospective study, 92 hemophilic patients with CHC who were treated with Peg-IFN-α/RBV were investigated...
2016: Journal of Research in Medical Sciences: the Official Journal of Isfahan University of Medical Sciences
https://www.readbyqxmd.com/read/27899013/in-vitro-antiviral-activity-of-ribavirin-against-severe-fever-with-thrombocytopenia-syndrome-virus
#17
Myung Jin Lee, Kye-Hyung Kim, Jongyoun Yi, Su Jin Choi, Pyoeng Gyun Choe, Wan Beom Park, Nam Joong Kim, Myoung-Don Oh
Background/Aims: Severe fever with thrombocytopenia syndrome (SFTS) is an emerging infectious disease caused by severe fever with thrombocytopenia syndrome virus (SFTSV), a novel bunyavirus. As yet, there is no effective antiviral therapy for SFTS. Ribavirin is a broad-spectrum antiviral agent, which has been tried for treatment of SFTS. In this study, antiviral activity of ribavirin against SFTSV has been investigated. Methods: Vero cell-grown SFTSV strain Gangwon/Korea/2012 was treated with ribavirin at various concentrations...
November 30, 2016: Korean Journal of Internal Medicine
https://www.readbyqxmd.com/read/27896858/efficacy-and-safety-of-simeprevir-and-sofosbuvir-with-and-without-ribavirin-in-subjects-with-recurrent-genotype-1-hepatitis-c-post-orthotopic-liver-transplant-the-randomized-galaxy-study
#18
Jacqueline G O'Leary, Robert J Fontana, Kimberly Brown, James R Burton, Roberto Firpi-Morell, Andrew Muir, Christopher O'Brien, Mordechai Rabinovitz, K Rajender Reddy, Robert Ryan, Adam Shprecher, Shirley Villadiego, Avinash Prabhakar, Robert S Brown
This prospective, randomized, phase 2 study in subjects with recurrent hepatitis C virus (HCV) genotype 1 post-orthotopic liver transplant evaluated once-daily simeprevir 150mg+sofosbuvir 400mg, with and without ribavirin 1,000mg. Primary endpoint was proportion of subjects with Week 12 sustained virologic response (SVR12). Thirty-three subjects without cirrhosis were randomized 1:1:1 into three arms (stratified by geno/subtype and Q80K): Arm 1, simeprevir+sofosbuvir+ribavirin, 12 weeks; Arm 2, simeprevir+sofosbuvir, 12 weeks; Arm 3, simeprevir+sofosbuvir, 24 weeks; 13 additional subjects (2 with cirrhosis, 11 without cirrhosis) entered Arm 3...
November 29, 2016: Transplant International: Official Journal of the European Society for Organ Transplantation
https://www.readbyqxmd.com/read/27896822/simeprevir-in-combination-with-sofosbuvir-in-treatment-na%C3%A3-ve-and-experienced-patients-with-hepatitis-c-virus-genotype-4-infection-a-phase-iii-open-label-single-arm-study-pluto
#19
M Buti, J L Calleja, S Lens, M Diago, E Ortega, J Crespo, R Planas, M Romero-Gómez, F G Rodríguez, J M Pascasio, B Fevery, D Kurland, C Corbett, R Kalmeijer, W Jessner
BACKGROUND: Hepatitis C virus (HCV) infection is a leading cause of liver cirrhosis and subsequent hepatocellular carcinoma. HCV genotype 4 is found widely in the Middle East, Egypt and Africa, and has also spread into Europe. There are limited data available regarding the use of direct-acting antiviral agents in HCV genotype 4-infected patients with cirrhosis. AIM: The Phase III, open-label, single-arm PLUTO study evaluated the efficacy and safety of 12 weeks of simeprevir (HCV NS3/4A protease inhibitor) plus sofosbuvir (HCV nucleotide-analogue NS5B polymerase inhibitor) in treatment-naïve and (peg)interferon ± ribavirin-experienced HCV genotype 4-infected patients, with or without compensated cirrhosis...
November 29, 2016: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/27896573/greater-decline-in-memory-and-global-neurocognitive-function-in-hiv-hepatitis-c-co-infected-than-in-hepatitis-c-mono-infected-patients-treated-with-pegylated-interferon-and-ribavirin
#20
Theodore R Miller, Jeffrey J Weiss, Norbert Bräu, Douglas T Dieterich, Alicia Stivala, Monica Rivera-Mindt
The human immunodeficiency virus (HIV), hepatitis C virus (HCV), and the treatment of HCV with pegylated interferon and ribavirin (IFN/RBV) have been associated with neurocognitive and psychiatric abnormalities. The goal of this research was to prospectively evaluate neurocognitive functioning among a group of HCV mono-infected and HIV/HCV co-infected patients during the first 24 weeks of IFN/RBV treatment while accounting for practice effects, normal variations in change over time, and variations in IFN/RBV treatment exposure...
November 28, 2016: Journal of Neurovirology
keyword
keyword
29712
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"